Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Abstract Introduction Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody–drug conjugate (ADC; or immunoconjugate) that delivers a cytotoxic payload, monomethyl auristatin F (MMAF), to...

Full description

Bibliographic Details
Main Authors: Asim V. Farooq, Simona Degli Esposti, Rakesh Popat, Praneetha Thulasi, Sagar Lonial, Ajay K. Nooka, Andrzej Jakubowiak, Douglas Sborov, Brian E. Zaugg, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Joanna Opalinska, January Baron, Trisha Piontek, Julie Byrne, Ira Gupta, Kathryn Colby
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-07-01
Series:Ophthalmology and Therapy
Subjects:
Antibody–drug conjugate
Belantamab mafodotin
Cornea
In vivo confocal microscopy
Microcyst-like epithelial changes
Monomethyl auristatin F
Online Access:https://doi.org/10.1007/s40123-020-00280-8

Internet

https://doi.org/10.1007/s40123-020-00280-8

Similar Items